The transaction, finalized following regulatory clearance, includes two FDA-approved rare tumor therapies: Ogsiveo for ...

Merck KGaA has concluded the previously announced acquisition of SpringWorks Therapeutics for an enterprise value of €3bn ($3.4bn), after receiving regulatory approvals and fulfilling customary ...

German pharmaceutical giant Merck has completed a €3 billion ($3. 5 billion) takeover of US biopharmaceutical company ...

A little over two months after it was announced, Germany-based life sciences firm Merck KGaA said Tuesday that it has ...

Merck KGaA, Darmstadt, Germany has closed the acquisition of SpringWorks Therapeutics Inc. for an enterprise value of $3.4 billion.

Explore SpringWorks Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for SWTX.

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) is up 47.80% year-to-date. Overall, SWTX ranks 14th on our list of the biotech ...

SpringWorks Therapeutics expects the EMA to rule on nirogacestat's marketing authorization for desmoid tumors in Q2 2025. Quiver AI Summary. SpringWorks Therapeutics, Inc. announced that it ...

Get the latest news on SpringWorks Therapeutics stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on SWTX performance ...

After months of discussion, Germany’s Merck KGaA said Monday it would buy SpringWorks Therapeutics for $47 a share in cash, a deal with an equity value of nearly $4 billion.